Moderna's Q1 2026: Revenue Gains Face a Large One-Off to Deliver a Grappling GAAP EPS

Financial snapshot

Revenue mix and growth: Total Q1 2026 revenue was $389 million, up by $281 million versus the year-ago period. U.S. revenue accounted for $78 million and international revenue for $311 million, underscoring a diversified geographic footprint as demand for vaccines and related products continues in international markets.

Cost of sales and one-off impact: Cost of sales totaled $955 million, comprising $895 million in third-party royalties and $38 million in inventory write-downs. Cost of sales rose by $865 million year over year, driven in large part by the $878 million litigation settlement-related expense recognized in Q1 2026 within third-party royalties. Excluding these settlement-related expenses, cost of sales declined versus 2025, aided by lower unutilized manufacturing costs and write-downs—partially offset by higher sales volume.

R&D and SG&A: Research and development expenses were $649 million, marking a 24% YoY decrease as Moderna winds down large Phase 3 respiratory programs and congenital CMV studies, with some offset from postmarketing commitments for COVID products. Selling, general and administrative expenses were $173 million, down 18% YoY due to lower personnel costs, reduced marketing, and lower external services.

Taxes and bottom line: Income taxes were not material. Net loss was $(1.3) billion for the quarter, with GAAP EPS of $(3.40), including the $0.9 billion non-recurring litigation settlement charge. The headline GAAP figures reflect this one-off item, which will color readers’ interpretation of the underlying business performance when compared to an adjusted or non-GAAP view.

Regulatory momentum and pipeline

Moderna notes European regulatory milestones, including approvals for mNEXSPIKE and its mCOMBRIAX flu-plus-COVID vaccine, expanding its portfolio beyond COVID vaccines and into broader infectious-disease protection. In oncology, the company initiated a Phase 3 study evaluating intismeran autogene as monotherapy and in combination with KEYTRUDA for high-risk Stage 1 non-small cell lung cancer, signaling continued diversification of its pipeline into cancer therapies.

Outlook and implications

Guidance remains: Moderna reiterates a target to deliver up to 10% revenue growth in 2026 and to achieve GAAP operating expense reductions, excluding the non-recurring litigation charge. The key question for investors is whether the 2026 plan can translate into durable revenue forecasts and margin stability once one-off charges fade from the ledger. In the near term, the market will weigh the company’s ability to convert EU approvals and Phase 3 readouts into sustainable EPS consensus improvements and whether earnings surprise metrics will reflect ongoing pipeline momentum rather than temporary cost headwinds.

For Moderna’s peers, the quarter reinforces a broader industry dynamic: one-off litigation or settlement costs can distort GAAP EPS in the short run, while investors increasingly care about whether the core growth engines—international demand, new vaccines, and oncology programs—can deliver a credible revenue forecast path. In that sense, Moderna’s Q1 reads as both a cautionary tale about the drag of non-operational charges and a case study in how regulatory and clinical milestones can reframe a company’s longer-term trajectory.

Conclusion: Growth under a ledger with a few caveats

Moderna’s first quarter of 2026 yields a nuanced verdict: revenue is growing, the pipeline is advancing, and European regulatory approvals broaden product appeal. Yet the GAAP bottom line remains depressed by a substantial one-off charge, shaping EPS and potentially shaping the stock’s near-term narrative. If the company can translate its EU approvals and Phase 3 progress into tangible revenue forecasts and margin improvements, the stock could begin to trade more on pipeline feasibility than on the drag from litigation settlements. In other words, the drama isn’t over—it’s unfolding in the feet of the financials as much as in the headlines of regulatory wins.